Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme | Zendy

Gregory G. Stone | Zendy; Paul Newell | Zendy; Leanne B. Gasink | Zendy; Helen Broadhurst | Zendy; Angela Wardman | Zendy; Katrina Yates | Zendy; Zhangjing Chen | Zendy; Jie Song | Zendy; Joseph W. Chow | Zendy

Open Access

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme

Author(s) -

Gregory G. Stone,

Paul Newell,

Leanne B. Gasink,

Helen Broadhurst,

Angela Wardman,

Katrina Yates,

Zhangjing Chen,

Jie Song,

Joseph W. Chow

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky204

Subject(s) - ceftazidime/avibactam , ceftazidime , pseudomonas aeruginosa , avibactam , enterobacteriaceae , microbiology and biotechnology , medicine , broth microdilution , carbapenem , biology , antibiotics , minimum inhibitory concentration , bacteria , escherichia coli , biochemistry , genetics , gene

This analysis evaluated the clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa isolates pooled from the adult Phase III clinical trials in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research